Phase Ib Study to Test the Safety and Potential Synergy of Pembrolizumab (Anti-PD-1) and AMG386 (Angiopoietin-2 (Ang-2) in Patients With Advanced Solid Tumor

Status: Active, no longer recruiting

Phase of Trial: Phase I

Latest Information Update: 22 Mar 2024

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Pembrolizumab (Primary) ; Trebananib (Primary)
Indications Colorectal cancer; Malignant melanoma; Ovarian cancer; Renal cell carcinoma; Solid tumours
Focus Adverse reactions

19 Mar 2024 Planned End Date changed from 31 Aug 2024 to 31 Aug 2025.
19 Mar 2024 Planned primary completion date changed from 28 Feb 2024 to 28 Feb 2025.
27 Mar 2023 Planned primary completion date changed from 28 Feb 2023 to 28 Feb 2024.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com